1. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. (6th April 2017) Authors: Norris, Stephen; Ramael, Steven; Ikushima, Ippei; Haazen, Wouter; Harada, Akiko; Moschetti, Viktoria; Imazu, Susumu; Reilly, Paul A.; Lang, Benjamin; Stangier, Joachim; Glund, Stephan Journal: British journal of clinical pharmacology Issue: Volume 83:Number 8(2017) Page Start: 1815 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitor. Issue 3 (24th August 2016) Authors: Timmers, Maarten; Van Broeck, Bianca; Ramael, Steven; Slemmon, John; De Waepenaert, Katja; Russu, Alberto; Bogert, Jennifer; Stieltjes, Hans; Shaw, Leslie M.; Engelborghs, Sebastiaan; Moechars, Dieder; Mercken, Marc; Liu, Enchi; Sinha, Vikash; Kemp, John; Van Nueten, Luc; Tritsmans, Luc; Streffer... Journal: Alzheimer's & dementia Issue: Volume 2:Issue 3(2016) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Issue 4 (April 2020) Authors: Fraser, Graeme L.; Lederman, Samuel; Waldbaum, Arthur; Kroll, Robin; Santoro, Nanette; Lee, Misun; Skillern, Laurence; Ramael, Steven Journal: Menopause Issue: Volume 27:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. Issue 6 (23rd August 2018) Authors: Rosenbrock, Holger; Desch, Michael; Kleiner, Oliver; Dorner‐Ciossek, Cornelia; Schmid, Bernhard; Keller, Sascha; Schlecker, Christina; Moschetti, Viktoria; Goetz, Sophia; Liesenfeld, Karl‐Heinz; Fillon, Gwenaelle; Giovannini, Riccardo; Ramael, Steven; Wunderlich, Glen; Wind, Sven Journal: Clinical and translational science Issue: Volume 11:Issue 6(2018) Page Start: 616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Issue 12 (December 2020) Authors: Santoro, Nanette; Waldbaum, Arthur; Lederman, Samuel; Kroll, Robin; Fraser, Graeme L.; Lademacher, Christopher; Skillern, Laurence; Young, James; Ramael, Steven Journal: Menopause Issue: Volume 27:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: a randomized, placebo-controlled, double-blind, dose-ranging study. (June 2019) Authors: Fraser, Graeme; Lederman, Samuel; Waldbaum, Arthur; Lee, Misun; Skillern, Laurence; Ramael, Steven Journal: Maturitas Issue: Volume 124(2019) Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Issue 9994 (15th August 2015) Authors: Glund, Stephan; Stangier, Joachim; Schmohl, Michael; Gansser, Dietmar; Norris, Stephen; van Ryn, Joanne; Lang, Benjamin; Ramael, Steven; Moschetti, Viktoria; Gruenenfelder, Fredrik; Reilly, Paul; Kreuzer, Jörg Journal: Lancet Issue: Volume 386:Issue 9994(2015) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinical evaluation of the NK3 receptor antagonist fezolinetant (a.k.a. ESN364) for the treatment of menopausal hot flashes. (September 2017) Authors: Depypere, Herman; Timmerman, Dirk; Donders, Gilbert; Sieprath, Peter; Ramael, Steven; Combalbert, Jean; Hoveyda, Hamid R.; Fraser, Graeme L. Journal: Maturitas Issue: Volume 103(2017) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pharmacokinetic–pharmacodynamic studies of the 11β‐hydroxysteroid dehydrogenase type 1 inhibitor MK‐0916 in healthy subjects. (December 2013) Authors: Wright, D. Hamish; Stone, Julie A.; Crumley, Tami M.; Wenning, Larissa; Zheng, Wei; Yan, Kerri; Yang, Amy Yifan; Sun, Li; Cilissen, Caroline; Ramael, Steven; Hermanowski‐Vosatka, Anne; Langdon, Ronald B.; Gottesdiener, Keith M.; Wagner, John A.; Lai, Eseng Journal: British journal of clinical pharmacology Issue: Volume 76:Number 6(2013:Dec.) Page Start: 917 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors. Issue 1 (December 2016) Authors: Van Broeck, Bianca; Timmers, Maarten; Ramael, Steven; Bogert, Jennifer; Shaw, Leslie; Mercken, Marc; Slemmon, John; Van Nueten, Luc; Engelborghs, Sebastiaan; Streffer, Johannes Journal: Alzheimer's research & therapy Issue: Volume 8:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗